<p>EDAP TMS S.A.（纳斯达克代码：EDAP）刚刚发布了 2024 财年的财报，结果令人印象深刻。该公司不仅超出了盈利预期，还在其核心的高强度聚焦超声（HIFU）业务领域展示了强劲的表现。让我们深入了解细节，看看这对投资者意味着什么。</p>
<p>强劲的财务表现</p>
<p>EDAP TMS 报告 2024 财年全球收入为 6920 万美元，比 2023 年增长了 5.7%。公司的 HIFU 业务部门作为其运营的支柱，全年 HIFU 收入增长了 15.3%，达到了 2570 万美元。这一增长证明了 Focal One 机器人 HIFU 系统的日益普及，成为泌尿科医生在前列腺癌管理中的首选技术。</p>
<p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a735b3d6ed38002.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a735b3d6ed38002.png"/></p>
<p>增长的关键驱动因素</p>
<p>1. Focal One 的采用增加：Focal One 系统持续获得关注，第四季度 HIFU 收入同比增长 15%，达 930 万美元。这一增长反映了越来越多的泌尿科中心对 Focal One 的强烈需求。</p>
<p>2. 拓展新市场：EDAP TMS 在阿肯色州、爱达荷州和乔治亚州等新州放置了首批 Focal One 系统，进一步扩大了在美国的市场份额。这一地理扩展是增长的关键驱动因素。</p>
<p>3. 经营租赁转换：第四季度的七笔美国销售中，有两笔包括来自波士顿布莱根妇女医院和德克萨斯州奥斯汀的圣大卫医院的经营租赁转换。这些转换反映了 EDAP 商业战略的强大和适应性。</p>
<p>4. 临床验证：在《欧洲泌尿学》上发表的 HIFI 研究涉及 3338 名患者，跨越 46 个治疗中心，提供了支持 HIFU 与根治性前列腺切除术比较的强有力证据。这一临床验证可能推动了 Focal One 平台的进一步采用。</p>
<p>5. 监管里程碑：针对深部浸润性子宫内膜异位症的 CE 标志批准代表了一个重要的监管里程碑，使 EDAP 能够在继续与子宫内膜异位症专家和思想领袖合作以进一步完善和扩展其临床开发工作的同时，进行受控市场进入。这扩大了 Focal One 平台的可寻址市场。</p>
<p>CE 标志批准的战略意义</p>
<p>针对深部浸润性子宫内膜异位症治疗的 CE 标志批准对 EDAP TMS 的市场扩展和竞争定位具有重要的战略意义。首先，该批准允许 EDAP TMS 进行受控市场进入，以治疗影响年轻生育年龄女性的严重和致残性疾病。这一里程碑使 EDAP TMS 能够进入一个新的市场细分，扩大其可寻址市场，超越前列腺应用。</p>
<p>其次，CE 标志批准使 EDAP TMS 在非侵入性治疗子宫内膜异位症的替代方案中处于领先地位。深部浸润性子宫内膜异位症是一种严重的慢性炎症性疾病，通常与生育障碍风险增加相关，并对心理和社会福祉产生深远影响。Focal One 机器人 HIFU 在这一适应症上的批准为女性提供了一种非侵入性的治疗替代方案，避免了与手术干预相关的显著并发症和较长的恢复时间。这使 EDAP TMS 成为提供创新和更少侵入性治疗选择的公司，增强了其在市场中的竞争地位。</p>
<p>第三，Focal One 机器人 HIFU 在深部浸润性子宫内膜异位症治疗中的批准为 EDAP TMS 开辟了新的收入来源。随着公司继续与子宫内膜异位症专家和思想领袖合作，进一步完善和扩展其临床开发工作，预计将在这一新市场细分中看到其技术的进一步采用。这反过来可以推动收入增长，并有助于公司的财务表现。</p>
<p>财务健康状况与前景</p>
<p>尽管表现强劲，EDAP TMS 仍处于亏损状态，运营费用为 4710 万欧元，而毛利润为 2660 万欧元。公司的现金状况从一年前的 4350 万欧元下降至 2980 万欧元，燃烧率值得关注。然而，CMS 的报销批准将 2025 年的报销金额提高了 5.4%，达到 9247 美元，为医院采用该技术创造了有利的经济条件。此外，医生的报销水平达到手术程序的 80%，消除了临床医生的财务障碍。</p>
<p>结论</p>
<p>EDAP TMS 的 2024 财年财报清晰地表明了公司强劲的表现和增长潜力。全年 HIFU 收入增长 15.3%，加上针对深部浸润性子宫内膜异位症治疗的 CE 标志批准的战略意义，使 EDAP TMS 在机器人能量治疗领域处于领先地位。尽管公司仍处于亏损状态，但强劲的财务表现和战略举措暗示了未来的良好前景。投资者应密切关注 EDAP TMS，因为它继续扩大市场份额并推动医疗技术领域的创新。</p>

EDAP

<p>EDAP TMS S.A. 报告了令人印象深刻的 2024 年全年收益，收入为 6920 万美元，超出预期，比 2023 年增长了 5.7%。HIFU（高强度聚焦超声）部门增长了 15.3%，达到 2570 万美元，主要得益于 Focal One 系统的采用和新市场的扩展。针对深部浸润性子宫内膜异位症的 CE 标志批准为公司开辟了新的收入来源，增强了 EDAP 的竞争地位。尽管公司运营亏损，但显示出强劲的增长潜力和战略举措，使其成为医疗技术领域投资者值得关注的前景</p>

<p>EDAP TMS S.A. (NASDAQ:EDAP) has just reported its full-year 2024 earnings, and the results are nothing short of impressive. The company not only beat earnings expectations but also showcased a robust performance in its core HIFU business segment. Let's dive into the details and understand what this means for investors.</p>
<div class="lb-trans"><p>EDAP TMS S.A.（纳斯达克代码：EDAP）刚刚发布了 2024 财年的财报，结果令人印象深刻。该公司不仅超出了盈利预期，还在其核心的高强度聚焦超声（HIFU）业务领域展示了强劲的表现。让我们深入了解细节，看看这对投资者意味着什么。</p>
</div><p>Strong Financial Performance</p>
<div class="lb-trans"><p>强劲的财务表现</p>
</div><p>EDAP TMS reported a full-year 2024 worldwide revenue of $69.2 million, representing a 5.7% growth over 2023. The company's HIFU business segment, which is the backbone of its operations, saw a remarkable 15.3% growth in full-year HIFU revenue, reaching $25.7 million. This growth is a testament to the increasing adoption of the Focal One Robotic HIFU system, which is becoming the go-to technology for urologists in the management of prostate cancer.</p>
<div class="lb-trans"><p>EDAP TMS 报告 2024 财年全球收入为 6920 万美元，比 2023 年增长了 5.7%。公司的 HIFU 业务部门作为其运营的支柱，全年 HIFU 收入增长了 15.3%，达到了 2570 万美元。这一增长证明了 Focal One 机器人 HIFU 系统的日益普及，成为泌尿科医生在前列腺癌管理中的首选技术。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a735b3d6ed38002.png" alt="" original-src="https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a735b3d6ed38002.png"/></p>
<p>Key Drivers of Growth</p>
<div class="lb-trans"><p>增长的关键驱动因素</p>
</div><p>1. Increased Adoption of Focal One: The Focal One system continues to gain traction, with HIFU revenues increasing by 15% year-over-year to $9.3 million in the fourth quarter. This growth reflects the strong demand for Focal One by an increasing number of urology centers.</p>
<div class="lb-trans"><p>1. Focal One 的采用增加：Focal One 系统持续获得关注，第四季度 HIFU 收入同比增长 15%，达 930 万美元。这一增长反映了越来越多的泌尿科中心对 Focal One 的强烈需求。</p>
</div><p>2. Expansion into New Markets: edap tms placed its first Focal One systems in new states like Arkansas, Idaho, and Georgia, further expanding its presence in the US. This geographic expansion is a key driver of growth.</p>
<div class="lb-trans"><p>2. 拓展新市场：EDAP TMS 在阿肯色州、爱达荷州和乔治亚州等新州放置了首批 Focal One 系统，进一步扩大了在美国的市场份额。这一地理扩展是增长的关键驱动因素。</p>
</div><p>3. Operating Lease Conversions: Two of the seven US sales in the fourth quarter included operating lease conversions from major hospitals like Brigham and Women’s Hospital in Boston and St. David’s Hospital in Austin, Texas. These conversions reflect the strength and adaptability of EDAP's commercial strategy.</p>
<div class="lb-trans"><p>3. 经营租赁转换：第四季度的七笔美国销售中，有两笔包括来自波士顿布莱根妇女医院和德克萨斯州奥斯汀的圣大卫医院的经营租赁转换。这些转换反映了 EDAP 商业战略的强大和适应性。</p>
</div><p>4. Clinical Validation: The publication of the HIFI study in European Urology, which involved 3,328 patients across 46 treatment centers, provides robust comparative evidence supporting HIFU versus radical prostatectomy. This clinical validation is likely driving further adoption of the Focal One platform.</p>
<div class="lb-trans"><p>4. 临床验证：在《欧洲泌尿学》上发表的 HIFI 研究涉及 3338 名患者，跨越 46 个治疗中心，提供了支持 HIFU 与根治性前列腺切除术比较的强有力证据。这一临床验证可能推动了 Focal One 平台的进一步采用。</p>
</div><p>5. Regulatory Milestones: The CE Mark approval for the treatment of deep infiltrating endometriosis represents a significant regulatory milestone that allows edap to proceed with a controlled market entry while continuing to work with endometriosis experts and thought leaders to further refine and expand their clinical development efforts. This expands the addressable market for the Focal One platform.</p>
<div class="lb-trans"><p>5. 监管里程碑：针对深部浸润性子宫内膜异位症的 CE 标志批准代表了一个重要的监管里程碑，使 EDAP 能够在继续与子宫内膜异位症专家和思想领袖合作以进一步完善和扩展其临床开发工作的同时，进行受控市场进入。这扩大了 Focal One 平台的可寻址市场。</p>
</div><p>Strategic Implications of the CE Mark Approval</p>
<div class="lb-trans"><p>CE 标志批准的战略意义</p>
</div><p>The CE Mark approval for deep infiltrating endometriosis treatment has significant strategic implications for EDAP TMS's market expansion and competitive positioning. Firstly, this approval allows EDAP TMS to proceed with a controlled market entry for treating deep infiltrating endometriosis, a severe and debilitating disease affecting young women in reproductive age. This milestone enables EDAP TMS to tap into a new market segment, expanding its addressable market beyond prostate applications.</p>
<div class="lb-trans"><p>针对深部浸润性子宫内膜异位症治疗的 CE 标志批准对 EDAP TMS 的市场扩展和竞争定位具有重要的战略意义。首先，该批准允许 EDAP TMS 进行受控市场进入，以治疗影响年轻生育年龄女性的严重和致残性疾病。这一里程碑使 EDAP TMS 能够进入一个新的市场细分，扩大其可寻址市场，超越前列腺应用。</p>
</div><p>Secondly, the CE Mark approval positions EDAP TMS as a leader in non-invasive treatment alternatives for endometriosis. Deep infiltrating endometriosis is a severe chronic inflammatory disease that is commonly associated with increased risk of fertility disorders and has a profound effect on psychological and social well-being. The approval of Focal One Robotic HIFU for this indication provides women with a non-invasive treatment alternative to surgical intervention, which is associated with notable complication side effects and extended recovery times. This positions EDAP TMS as a company that offers innovative and less invasive treatment options, enhancing its competitive positioning in the market.</p>
<div class="lb-trans"><p>其次，CE 标志批准使 EDAP TMS 在非侵入性治疗子宫内膜异位症的替代方案中处于领先地位。深部浸润性子宫内膜异位症是一种严重的慢性炎症性疾病，通常与生育障碍风险增加相关，并对心理和社会福祉产生深远影响。Focal One 机器人 HIFU 在这一适应症上的批准为女性提供了一种非侵入性的治疗替代方案，避免了与手术干预相关的显著并发症和较长的恢复时间。这使 EDAP TMS 成为提供创新和更少侵入性治疗选择的公司，增强了其在市场中的竞争地位。</p>
</div><p>Thirdly, the approval of Focal One Robotic HIFU for deep infiltrating endometriosis treatment opens up new revenue streams for EDAP TMS. As the company continues to work with endometriosis experts and thought leaders to further refine and expand its clinical development efforts, it can expect to see increased adoption of its technology in this new market segment. This, in turn, can drive revenue growth and contribute to the company's financial performance.</p>
<div class="lb-trans"><p>第三，Focal One 机器人 HIFU 在深部浸润性子宫内膜异位症治疗中的批准为 EDAP TMS 开辟了新的收入来源。随着公司继续与子宫内膜异位症专家和思想领袖合作，进一步完善和扩展其临床开发工作，预计将在这一新市场细分中看到其技术的进一步采用。这反过来可以推动收入增长，并有助于公司的财务表现。</p>
</div><p>Financial Health and Outlook</p>
<div class="lb-trans"><p>财务健康状况与前景</p>
</div><p>Despite the strong performance, EDAP TMS still operates at a loss with operating expenses of €47.1 million against gross profit of €26.6 million. The company's cash position declined to €29.8 million from €43.5 million a year ago, representing a burn rate that bears monitoring. However, the CMS reimbursement approval with a 5.4% increase to $9,247 for 2025 creates a compelling economic case for hospitals to adopt the technology. Additionally, physician reimbursement at 80% of surgical procedure levels removes financial barriers for clinicians.</p>
<div class="lb-trans"><p>尽管表现强劲，EDAP TMS 仍处于亏损状态，运营费用为 4710 万欧元，而毛利润为 2660 万欧元。公司的现金状况从一年前的 4350 万欧元下降至 2980 万欧元，燃烧率值得关注。然而，CMS 的报销批准将 2025 年的报销金额提高了 5.4%，达到 9247 美元，为医院采用该技术创造了有利的经济条件。此外，医生的报销水平达到手术程序的 80%，消除了临床医生的财务障碍。</p>
</div><p>Conclusion</p>
<div class="lb-trans"><p>结论</p>
</div><p>EDAP TMS's full-year 2024 earnings report is a clear indication of the company's strong performance and growth potential. The 15.3% growth in full-year HIFU revenue, coupled with the strategic implications of the CE Mark approval for deep infiltrating endometriosis treatment, positions EDAP TMS as a leader in robotic energy-based therapies. While the company still operates at a loss, the strong financial performance and strategic initiatives suggest a promising outlook for the future. Investors should keep a close eye on EDAP TMS as it continues to expand its market presence and drive innovation in the medical technology sector.</p>
<div class="lb-trans"><p>EDAP TMS 的 2024 财年财报清晰地表明了公司强劲的表现和增长潜力。全年 HIFU 收入增长 15.3%，加上针对深部浸润性子宫内膜异位症治疗的 CE 标志批准的战略意义，使 EDAP TMS 在机器人能量治疗领域处于领先地位。尽管公司仍处于亏损状态，但强劲的财务表现和战略举措暗示了未来的良好前景。投资者应密切关注 EDAP TMS，因为它继续扩大市场份额并推动医疗技术领域的创新。</p>
</div>

EDAP TMS 2024 全年收益：超出市场预期